Q2 EPS Forecast for Marker Therapeutics Cut by Analyst

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Brookline Capital Markets reduced their Q2 2026 earnings per share (EPS) estimates for Marker Therapeutics in a report released on Friday, May 15th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their previous forecast of ($0.27). The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.18) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.53) EPS, FY2028 earnings at $1.44 EPS, FY2029 earnings at $4.97 EPS and FY2030 earnings at $14.34 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Price Performance

MRKR stock opened at $1.39 on Wednesday. The business has a 50-day moving average price of $1.44 and a 200 day moving average price of $1.44. The company has a market capitalization of $23.17 million, a P/E ratio of -2.28 and a beta of 1.43. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%.

Hedge Funds Weigh In On Marker Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its holdings in Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares in the last quarter. Jane Street Group LLC bought a new position in Marker Therapeutics in the second quarter worth about $33,000. LPL Financial LLC raised its holdings in Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Marker Therapeutics in the third quarter worth about $25,000. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.